8-ethoxy-3-(4-nitrophenyl)-2H-chromen-2-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: 8-ethoxy-3-(4-nitrophenyl)-2H-chromen-2-one
• 英文别名: 8-ethoxy-3-(4-nitrophenyl)chromen-2-one
• 化学式: C₁₇H₁₃NO₅
• 分子量: 311.294
• InChiKey: ACPZWFXITZCSCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  81.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  在 potassium hydroxide 作用下， 以82.5 %的产率得到8-ethoxy-3-(4-nitrophenyl)-2H-chromen-2-one
  参考文献：
  名称：

  Synthesis, Molecular Modeling and Cytotoxicity Study of New 3-Phenyl Coumarin Derivatives against in vitro Cell Lines

  摘要：

  In pursuit of more effective cancer treatments, researchers embarked on a study to enhance the coumarin derivative’s therapeutic potential. These compounds, known for their anticancer properties, have faced challenges such as increased toxicity and drug resistance. The research aimed to design, synthesize and assess new 3-phenyl coumarin derivatives specifically for breast and lung cancer treatment. Utilizing 3-oxoacyl-reductase (1T8I), a series of compounds were synthesized from aromatic aldehydes and phenylacetic acid. Among the synthesized 11 compounds that were examined, compounds C01, C04, C05 and C08 had significant cytotoxic effects on both MCF-7 and MRC-5 cell lines. Particularly, compound C08, featuring ethoxy and nitrate substitution, exhibited remarkable potential against both cancer cell lines, emphasizing its promise for further exploration in cancer therapy.

  DOI：

  10.14233/ajchem.2024.31269

文献信息

• Structure-Based Optimization of Coumarin hA₃ Adenosine Receptor Antagonists
  作者：Maria João Matos、Santiago Vilar、Saleta Vazquez-Rodriguez、Sonja Kachler、Karl-Norbert Klotz、Michela Buccioni、Giovanna Delogu、Lourdes Santana、Eugenio Uriarte、Fernanda Borges

  DOI：10.1021/acs.jmedchem.9b01572

  日期：2020.3.12

  Adenosine receptors participate in many physiological functions. Molecules that may selectively interact with one of the receptors are favorable multifunctional chemical entities to treat or decelerate the evolution of different diseases. 3-Arylcoumarins have already been studied as neuroprotective agents by our group. Here, differently 8-substituted 3-arylcoumarins are complementarily studied as ligands of adenosine receptors, performing radioligand binding assays. Among the synthesized compounds, selective A(3) receptor antagonists were found. 3-(4-Bromophenyl)-8-hydroxycoumarin (compound 4) displayed the highest potency and selectivity as A(3) receptor antagonist (K-i = 258 nM). An analysis of its X-ray diffraction provided detailed information on its structure. Further evaluation of a selected series of compounds indicated that it is the nature and position of the substituents that determine their activity and selectivity. Theoretical modeling calculations corroborate and explain the experimental data, suggesting this novel scaffold can be involved in the generation of candidates as multitarget drugs.
• Synthesis, Molecular Modeling and Cytotoxicity Study of New 3-Phenyl Coumarin Derivatives against in vitro Cell Lines
  作者：Anuruddha Chabukswar、Prajakta V. Adsule、Swati Jagdale、Dishank V. Purandare、Kunal Raut、Yash Kale

  DOI：10.14233/ajchem.2024.31269

  日期：——

  In pursuit of more effective cancer treatments, researchers embarked on a study to enhance the coumarin derivative’s therapeutic potential. These compounds, known for their anticancer properties, have faced challenges such as increased toxicity and drug resistance. The research aimed to design, synthesize and assess new 3-phenyl coumarin derivatives specifically for breast and lung cancer treatment. Utilizing 3-oxoacyl-reductase (1T8I), a series of compounds were synthesized from aromatic aldehydes and phenylacetic acid. Among the synthesized 11 compounds that were examined, compounds C01, C04, C05 and C08 had significant cytotoxic effects on both MCF-7 and MRC-5 cell lines. Particularly, compound C08, featuring ethoxy and nitrate substitution, exhibited remarkable potential against both cancer cell lines, emphasizing its promise for further exploration in cancer therapy.